Revenue from Contracts with Customers Revenue from Contracts with Customers (Notes)

3 Months Ended

Mar. 28, 2025

Revenue from Contract with Customer [Abstract]

Revenue from Contract with Customer [Text Block]

4. Revenue from Contracts with Customers

Product Sales Revenue

See Note 15 for disaggregation of the Company's net sales by product family.

Reserves for variable consideration

The following table reflects activity in the Company's sales reserve accounts:

	Rebates and Chargebacks (1)		Product Returns		Other Sales Deductions		Total
Balance as of December 29, 2023	$	201.6	$	14.5	$	11.3	$	227.4
Provisions	401.2		4.2		14.2		419.6
Payments or credits	(397.0)		(5.7)		(13.5)		(416.2)
Balance as of March 29, 2024	$	205.8	$	13.0	$	12.0	$	230.8
Balance as of December 27, 2024	$	197.5	$	14.8	$	16.5	$	228.8
Provisions	379.9		2.1		17.2		399.2
Payments or credits	(361.1)		(0.8)		(12.1)		(374.0)
Balance as of March 28, 2025	$	216.3	$	16.1	$	21.6	$	254.0

(1)Amounts classified within accrued and other current liabilities in the unaudited condensed consolidated balance sheets are comprised of $25.2 million and $26.4 million of accrued Medicaid and $55.2 million and $61.4 million of accrued rebates, of which $49.4 million and $39.8 million related to Acthar Managed Care and Medicare, as of March 28, 2025 and December 27, 2024, respectively.

Product sales transferred to customers at a point in time and over time were as follows:

	Three Months Ended
	March 28, 2025		March 29, 2024
Product sales transferred at a point in time	85.1	%	84.7	%
Product sales transferred over time	14.9		15.3

Transaction price allocated to the remaining performance obligations

The following table includes estimated revenue from contracts extending greater than one year for certain of the Company's hospital products that are expected to be recognized in the future related to performance obligations that were unsatisfied or partially unsatisfied as of March 28, 2025:

Remainder of Fiscal 2025	$	54.3
Fiscal 2026	62.5
Fiscal 2027	26.1
Thereafter	10.3

Costs to fulfill a contract

As of March 28, 2025 and December 27, 2024, the total net book value of the devices used in the Company's portfolio of drug-device combination products, which are used in satisfying future performance obligations and reflected in property, plant and equipment, net, on the consolidated balance sheets was $44.7 million and $37.8 million, respectively. The associated depreciation expense recognized during the three months ended March 28, 2025 and March 29, 2024 was $1.5 million and $0.4 million, respectively.